Showing results (1-10 of 27) with videos related to
Sort By:
Pageof 3
Current HIV Research|November 30, 2007
Clade specific neutralising vaccines for HIV: an appropriate target?Aine McKnight, Marlén M I Aasa-ChapmanBMC Immunology|March 20, 2010
Anti-infective activity of apolipoprotein domain derived peptides in vitro: identification of novel antimicrobial peptides related to apolipoprotein B with anti-HIV activityBridie A Kelly, Ian Harrison, Aine McKnight, et al.Blood|February 25, 2005
HIV-1 incorporates ABO histo-blood group antigens that sensitize virions to complement-mediated inactivationStuart J D Neil, Aine McKnight, Kenth Gustafsson, et al.Virology|May 23, 2006
Primary CCR5 only using HIV-1 isolates does not accurately represent the in vivo replicating quasi-speciesMarlén M I Aasa-Chapman, Keith Aubin, Ian Williams, et al.Journal of Virology|October 17, 2006
Novel envelope determinants for CCR3 use by human immunodeficiency virusMarlén M I Aasa-Chapman, Craig R Seymour, Ian Williams, et al.Journal of Virology|July 15, 2005
An envelope-determined, pH-independent endocytic route of viral entry determines the susceptibility of human immunodeficiency virus type 1 (HIV-1) and HIV-2 to Lv2 restrictionDavid Marchant, Stuart J D Neil, Keith Aubin, et al.Retrovirology|May 29, 2010
Modulation of HIV-1 macrophage-tropism among R5 envelopes occurs before detection of neutralizing antibodiesKathryn H Richards, Marlén Mi Aasa-Chapman, Aine McKnight, et al.AIDS (London, England)|January 31, 2003
CD4-dependent and CD4-independent HIV-2: consequences for neutralizationElaine R Thomas, Christine Shotton, Robin A Weiss, et al.AIDS (London, England)|June 26, 2003
Productive HIV-2 infection in the brain is restricted to macrophages/microgliaAndreas Mörner, J Alero Thomas, Ewa Björling, et al.Journal of Virology|January 30, 2004
Lv2, a novel postentry restriction, is mediated by both capsid and envelopeChristian Schmitz, David Marchant, Stuart J D Neil, et al.Pageof 3